Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02578771 · ClinicalTrials.gov registry record · Phase 3

Pilot Clinical Evaluation to Characterize in Vivo Effects of Topically Applied ZuraPrep & ZuraPrep Vehicle

A Phase 3 study, sponsored by Zurex Pharma.

Completed
Registry status
Phase 3
Development phase
123
Enrollment target

NCT02578771 is a Phase 3 study that has completed, run by Zurex Pharma. The registered enrollment target is 123 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02578771, a Phase 3 study, has completed, sponsored by Zurex Pharma.

COMPLETED
Registry status
Phase 3
Development phase
123 participants
Enrollment target

Study Summary

ZuraPrep is being evaluated for efficacy as a preoperative skin preparation solution to demonstrate its immediate and persistent antimicrobial properties. At least 72 subjects will be randomized utilizing bilateral applications on abdomen and groin. ZuraPrep active product and reference positive control will be compared; ZuraPrep non-active and negative control will be compared. Each subject will receive two of the planned treatments, one on the left side of body and one of the right. Study duration for subjects - 3 to 4 weeks.

Interventions

  • OTHER Normal Saline
  • DRUG ZuraPrep with 70% IPA
  • DRUG ZuraPrep without 70% IPA
  • DRUG ChloraPrep CHG/IPA Teal Tint

Trial Details

FieldValue
Enrollment Target 123 participants
Start Date 2015-10
Est. Completion 2016-01
Phase Phase 3

Sponsor

Zurex Pharma

9 total trials

What the Registry Record Tells You About NCT02578771

The ClinicalTrials.gov registry entry for NCT02578771 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zurex Pharma, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which Normal Saline is the first listed.

NCT02578771 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02578771 about?

NCT02578771 is a clinical study titled "Pilot Clinical Evaluation to Characterize in Vivo Effects of Topically Applied ZuraPrep & ZuraPrep Vehicle". ZuraPrep is being evaluated for efficacy as a preoperative skin preparation solution to demonstrate its immediate and persistent antimicrobial properties. At least 72 subjects will be randomized utilizing bilateral applications on abdomen and groin. ZuraPrep active product and reference positive con...

What is the current status of trial NCT02578771?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 123 participants. The study started on 2015-10. Estimated completion is 2016-01.

What interventions are being tested in trial NCT02578771?

The interventions under investigation include: Normal Saline (OTHER), ZuraPrep with 70% IPA (DRUG), ZuraPrep without 70% IPA (DRUG), ChloraPrep CHG/IPA Teal Tint (DRUG).

Who is sponsoring clinical trial NCT02578771?

This trial is sponsored by Zurex Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.